Clinical Trial Update: Postlicensure Observational Safety Study of 13vPnC Administered to Infants and Toddlers

View source ↗

Summary

This postlicensure observational safety study evaluated the safety of the 13-valent pneumococcal conjugate vaccine (13vPnC) administered to infants and toddlers…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Disease

Drugs mentioned

• Prevnar 13 (pneumococcal conjugate vaccine)

Snippet

Sponsor: Pfizer | Conditions: Pneumococcal Disease | Status: COMPLETED | Results posted: 2014-07-14